Haemonetics Corp. (HAE) stock forecast and price target
Price $122.94 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($122.94)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends March 31, 2027 | $5.34 | +7.7% | $1.4B |
| Next fiscal year ends March 31, 2028 | $6.20 | +16.1% | $1.6B |
| Next quarter ends December 31, 2026 | $1.27 | −2.8% | $358M |
| Quarter after ends March 31, 2027 | $1.58 | +22.6% | $388M |
Consensus of the analysts covering Haemonetics, updated daily. In the last 30 days 3 estimates were raised and 2 lowered.
Our model vs. Wall Street
Analysts see 17.6% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Haemonetics’s intrinsic value about 37% below today’s market value, and it scores 1.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Haemonetics stock price target?
The average 12-month target from 11 analysts is $144.55, 17.6% above the current price of $122.94 Targets range from $115.00 to $165.00.
Is Haemonetics a buy according to analysts?
The consensus rating is “Buy” (4 strong buy, 6 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Haemonetics expected to earn?
Analysts expect EPS of $5.34 for the fiscal year ending March 31, 2027 and $6.20 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.